Investigating the role of extracellular DNA in gastric cancer development
The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric Cancer: an Exploratory Multicenter Prospective Observational Clinical Study
This study is trying to see how changes in a type of DNA found outside of cells might affect the development of gastric cancer in patients with precancerous lesions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT05956847 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the significance of extracellular DNA (ecDNA) in the occurrence and progression of gastric cancer. By conducting gastroscopy biopsies on patients with precancerous lesions, the study will monitor changes in ecDNA expression in the gastric mucosa over time. The goal is to understand how these changes relate to gastric cancer development and to potentially guide future treatment strategies. The study involves collaboration among multiple endoscopic centers to ensure a comprehensive approach to data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-80 who are undergoing gastroscopy for gastric precancerous lesions or gastric adenocarcinoma.
Not a fit: Patients with other malignant tumors of the stomach or those who do not consent to the use of their specimens for research may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and treatment strategies for gastric cancer.
How similar studies have performed: While the role of ecDNA in cancer is a growing area of interest, this specific approach to studying its impact on gastric cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age: 18-80 years old; 2. Patients who plan to undergo gastroscopy at the endoscopic center and patients who undergo surgical treatment for gastric adenocarcinoma; 3. Endoscopy doctors believe that pathological biopsy is necessary to clarify the pathological diagnosis; 4. No serious diseases or other systemic malignancies in terms of physical and mental health; 5. More than one item of non Atrophic gastritis, Atrophic gastritis, intestinal metaplasia, heterogeneous hyperplasia (low grade intraepithelial neoplasia and high grade intraepithelial neoplasia), and gastric adenocarcinoma; 6. Sign an informed consent form; Exclusion Criteria： 1. Pathological results indicate other malignant tumors of the stomach, such as stromal tumors and lymphoma; 2. The patient and their family members do not agree to use the specimen for later research projects; 3. Before gastroscopy or surgery, neoadjuvant therapy or combined with other malignant tumors; 4. Non R0 resected gastric cancer patients; 5. Pregnant or lactating women; 6. Have a history of drug abuse such as alcohol and tobacco.
Where this trial is running
Xi'an, Shaanxi
- Xijing Hospital of Digestive Diseases — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Guo Xin — Xijing 986 Hospital
- Study coordinator: wei jiangpeng, PhD
- Email: 15389058362@163.com
- Phone: 15389058362
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.